Myrexis Inc was incorporated as Myriad Pharmaceuticals, Inc. in Delaware in January 2009 as a new, wholly owned subsidiary of Myriad Genetics, Inc., in order to effect the separation and spin-off of Myriad Genetics' research and drug development businesses as a stand-alone, independent, publicly traded company. In connection with the formation of this new subsidiary, Myriad Genetics' existing subsidiary, Myriad Pharmaceuticals, Inc., changed its corporate name to Myriad Therapeutics, Inc. Effective July 1, 2010, the Company changed its name from Myriad Pharmaceuticals, Inc. to Myrexis, Inc. The Company is engaged in evaluating strategic alternatives, including focusing on identifying, evaluating and making financial investments in life sciences assets.
Benzinga is a fast-growing, dynamic and innovative financial media outlet that empowers investors with high-quality, unique content.